Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 1/7/2020
SIETES contiene 93059 citas

 
 
 1 a 20 de 1096 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Anderson TS, Odden MC, Penko J, et al.. Generalizability of clinical trials supporting the 2017 American College of Cardiology/American Heart Association blood pressure guideline. JAMA Intern Med 2020:16 de marzo. [Ref.ID 103580]
3. Cita con resumen
Healy D, Mangin D. Clinical judgments, not algorithms, are key to patient safety. BMJ 2019;367:2 de octubre. [Ref.ID 103204]
4.Enlace a cita original Cita con resumen
Desai RJ, Sarpatwari A, Dejene S, Khan NF, Lii J, Rogers JR, Dutcher SK, Raofi S, Bohn J, Connolly JG, Fischer MA, Kesselheim AS, Gagne JJ. Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims. PLOS Medicine 2019:13 de marzo. [Ref.ID 103076]
5. Cita con resumen
Busse JW, Wang L, Kamaleldin M, Craigie S, Riva JJ, Montoya L, et al.. Opioids for chronic noncancer pain. A systematic review and meta-analysis. JAMA 2018;320:18 de diciembre. [Ref.ID 102914]
6.Enlace a cita original Cita con resumen
Baillargeon J, Kuo YF, Westra JR, Urban RJ, Goodwin JS. Testosterone prescribing in the United States, 2002-2016. JAMA 2018;319:10 de julio. [Ref.ID 102792]
7.Enlace a cita original Cita con resumen
Kitchlu A, Shapiro J, Amir E, Garg AX, Kim J, Wald R, Harel Z. Representation of patients with chronic kidney disease in trials of cancer therapy. JAMA 2018;319:19 de junio. [Ref.ID 102790]
8.Enlace a cita originalTiene citas relacionadas Cita con resumen
Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med 2018;381:29 de agosto. [Ref.ID 102748]
9.Tiene citas relacionadas Cita con resumen
Rasmussen SA, Barfield W, Honein MA. Protecting mothers and babies — A delicate balancing act. N Engl J Med 2018:24 de julio. [Ref.ID 102747]
10.Enlace a cita originalTiene citas relacionadas Cita con resumen
Hopcroft K. Effectiveness of antidepressants - should we rethink treatment duration?. BMJ 2018;361:24 de abril. [Ref.ID 102576]
11.Enlace a cita original Cita con resumen
Garattini S, Bertele V. Benefits, benefits, once more benefits... with no risk? Stop overlooking the harms of medicines. Eur J Clin Pharmacol 2018;74:marzo. [Ref.ID 102550]
13. Cita con resumen
Go AS, Singer DE, Toh S, Cheetham TC, Reichman ME, Graham DJ, Southworth MR, Zhang R, Izem R, Goulding MR, Houstoun M, Mott K, Sung SH, Gagne JJ. Outcomes of dabigatran and warfarin for atrial fibrillation in contemporary practice: a retrospective cohort study. Ann Intern Med 2017;167:845-54. [Ref.ID 102196]
15. Cita con resumen
Fanning L, Ilomäki J, Bell JS, Darzinš P. The representativeness of direct oral anticoagulant clinical trials to hospitalized patients with atrial fibrillation. Eur J Clin Pharmacol 2017;73:1427-36. [Ref.ID 102129]
18. Cita con resumen
Mazlan-Kepli W, Macisaac RL, Walters M, Bath PMW, Dawson J, on behalf of the VISTA Collaborators. Interruption to antiplatelet therapy early after acute ischaemic stroke: a nested case–control study. Br J Clin Pharmacol 2017;83:2045-55. [Ref.ID 102030]
19.Tiene citas relacionadas Cita con resumen
Gieling EM, van den Ham HA, van Onzenoort H, Bos J, Kramers C, de Boer A, de Vries F, Burden AM. Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study. Br J Clin Pharmacol 2017;83:1844-59. [Ref.ID 102014]
20. Cita con resumen
Lehto M, Niiranen J, Korhonen P, Mehtälä J, Khanfir H, Hoti F, Lassila R, Raatikainen P. Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation: results from the nationwide FinWAF Registry. Pharmacoepidemiol Drug Saf 2017;26:657-65. [Ref.ID 101963]
Seleccionar todas
 
 1 a 20 de 1096 siguiente >>